Skip to content
Review

Gasdermin-mediated pyroptosis as a prognostic biomarker and therapeutic target in hepatocellular carcinoma.

Aug 2026 · Clinical Immunology · Vol 288, pp. 110765 · 0 citations · 231 references
Medicine

TL;DR

Examination of molecular circuitry linking pyroptosis with inflammasomes, metabolic stress, mitochondrial dysfunction, hypoxia, and epigenetic regulation in HCC suggests regulated pyroptosis may represent a promising immunomodulatory framework for improving precision therapy in HCC.

Abstract

Hepatocellular carcinoma (HCC) develops within a chronically inflamed and immunologically dysregulated hepatic microenvironment that contributes to therapeutic resistance and disease progression. Gasdermin-mediated pyroptosis has emerged as a context-dependent inflammatory cell-death program capable of reshaping antitumor immunity, stromal remodeling, and immune checkpoint responsiveness. Acute and localized activation of GSDMD or GSDME may enhance immune-cell recruitment and tumor antigen exposure, whereas persistent pyroptotic signaling promotes fibrosis, angiogenesis, and immunosuppressive remodeling. This review examines the molecular circuitry linking pyroptosis with inflammasomes, metabolic stress, mitochondrial dysfunction, hypoxia, and epigenetic regulation in HCC. We further discuss how single-cell and spatial transcriptomic approaches reveal distinct pyroptotic immune niches associated with macrophage polarization, T-cell infiltration, and therapeutic response. Emerging therapeutic strategies including inflammasome modulation, gasdermin-targeted interventions, metabolic sensitization, and combination immunotherapy are also evaluated. Collectively, regulated pyroptosis may represent a promising immunomodulatory framework for improving precision therapy in HCC.

View source

Similar papers

Review Open access Sep 2026

Regulatory roles of pyroptosis-associated lncRnas in breast cancer progression and immune microenvironment.

Clinical translation remains limited by dependence on retrospective transcriptomic datasets, insufficient mechanistic validation, lack of standardized assays, and scarce prospective clinical evidence, but pyroptosis-associated lncRNAs represent a promising link between tumor progression and immune regulation, with cons...

Chou-Yi Hsu, Bilal Abdulmajeed Mukhlif, O. Nematov et al. · 0 citations
Review Sep 2026

Pyroptosis in Triple-Negative Breast Cancer: From Inflammasome Signaling to Tumor Immune Remodeling and Translational Therapeutic Strategies.

This review critically examines pyroptosis-TIME crosstalk in TNBC, prioritizing TNBC and breast cancer evidence while using non-breast cancer findings only as mechanistic comparators when they clarify conserved inflammasome or gasdermin biology.

Qamar Abuhassan, M. Al-Khreisat, R. Roopashree et al. · 1 citation
Review Open access Aug 2026

Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects

This review systematically summarizes the molecular regulatory mechanisms of pyroptosis, encompassing classical and non-classical inflammasome pathways, activation and modulation of gasdermin proteins, and the intricate signaling networks involved.

Yi Shen, Qiang-Qiang Zheng, Yang Yuan et al. · 0 citations
Sep 2026

CD36-Pocket Targeting Induces Metabolic Collapse and Disulfidoptosis for Sonodynamic Immunometabolic Therapy of Liver Cancer.

Obesity-driven lipid accumulation in hepatocellular carcinoma (HCC) establishes a coupled metabolic-immunosuppressive niche that fuels tumor progression and undermines anti-tumor immunity. Through multiplexed immunofluorescence profiling of clinical HCC tissues stratified by visceral adiposity, we explicitly map this l...

Liang Zhang, Meng-Xin He, Yao-Wu Lu et al. · 0 citations
Review Aug 2026

Pyroptosis‐Inducing Nanomedicine for Cancer Immunotherapy: Mechanisms and Emerging Strategies

This review summarizes recent progress in the molecular mechanisms of pyroptosis and highlights emerging nanomedicine strategies designed to precisely induce pyroptosis within tumors to inspire next‐generation immunotherapeutic interventions against cancer.

Pengfei Wang, Xinxin Sun, Yuning Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.